Current understanding of the pathophysiology of portal hypertension has resulted in therapeutic approaches aimed at correcting the increased splanchnic blood flow and some of which have been already used in clinical practice. Recently new perspectives opened and erstwhile paradigm has been changed to focus on increased resistance to portal blood flow and the formation of portosystemic collateralization. Several studies revealed the clear-cut mechanisms of hepatic endothelial dysfunction and abnormal angiogenesis contributing to the development of portal hypertension. Thus the modulations of hyperdynamic circulation or angiogenesis seem to be valuable therapeutic targets. In the current review update, we discuss the multidisciplinary management of modulating hepatic vascular resistance and abnormal angiogenesis associated with portal hypertension. However, these new pharmacological approaches are still under investigation and widescale clinical application are needed to develop effective strategies. 
2) 간내 NO 생체이용효율 촉진 약물
간경변증에서 NO 생체이용효율의 감소는 간내 혈관 저 항을 증가시키는 주요한 원인이고, eNOS mRNA 발현 및 (Fig. 2) . 51, 55, 56 동물모델과 임상시험에서 statin은 간경변증의 간 내피세 Fig. 2 . Mechanisms mediating the decrease in hepatic resistance by statins. Statins increase eNOS expression and activity. The most immediate effect of statins on endothelial NO production is an increase in eNOS phosphorylation, with subsequent increased activity. This is mediated by the activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway that leads to an increase in Akt phosphorylation with ensuing eNOS phosphorylation. Statins reduce the expression of the eNOS inhibitory protein caveolin-1 and increase the interaction of eNOS with its stimulatory protein Hsp90. These effects occur slower than the PI3K/Akt pathway activation. Statins also increase the expression of GTP cyclohydrolase I (GTPCH), the rate-limiting enzyme for de novo synthesis of tetrahydrobiopterin (BH4), a cofactor that increases eNOS activity by preventing eNOS uncoupling and, thus, superoxide generation. Statins also upregulate eNOS expression by increasing eNOS mRNA stability. Lastly, statins inhibit hepatic RhoA/Rho kinase signalling, which increases eNOS expression and decreases hepatic stellate cell (HSC) contractility (modified from Bosch et al., J of Hepatology 2010). (Fig. 3) . 59 또한 
